Ophthotech Corporation (OPHT) : Fridays money flow indicated an uptick to downtick ratio was at 1.16. The total value of inflow transactions on upticks was $6.19 million, whereas, the total value of outflow trades on downticks was $5.33 million. The total money flow was $0.85 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.64 million. The total value of the trades done on upticks was $1.28 million. Downticks saw transactions worth $0.65 million. The total uptick to downtick ratio stood at 1.98, mildly in favor of the bulls. Ophthotech Corporation (OPHT) was trading with a -3.11% change over previous days close. It fell $1.65 during the day and reached $51.32. The stock was -3.57% compared to the previous weeks close.
The company Insiders own 2% of Ophthotech Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -83.7% . During last six month period, the net percent change held by insiders has seen a change of -29.3%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President) of Ophthotech Corp., Patel Samir Chandrakant had sold 20,000 shares worth of $1,056,000 in a transaction dated August 29, 2016. In this transaction, 20,000 shares were sold at $52.8 per share.
Ophthotech Corporation (NASDAQ:OPHT): stock was range-bound between the intraday low of $50.7311 and the intraday high of $53.595 after having opened at $53.16 on Fridays session. The stock finally closed in the red at $53.16, a loss of -3.11%. The stock remained in the red for the whole trading day. The total traded volume was 426,319 shares. The stock failed to cross $53.595 in Fridays trading. The stocks closing price on Thursday was $52.97.
Ophthotech Corporation (OPHT) : During the past 4 weeks, traders have been relatively bearish on Ophthotech Corporation (OPHT), hence the stock is down -15.94% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.05% relative to the S&P 500. The 4-week change in the price of the stock is -16.05% and the stock has fallen -3.57% in the past 1 week.
Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.